Cell Differentiation and Turnover Package (TOP)

Dosing and Administration of drugs: used internally; dose, depends on the disease; hr.miyeloleykoz: initial dose 20 - 40 mg / kg / day once, on 15 - 30 mg / kg / day Ceftriaxone Contractions maintenance dose, with an acute: 30 - 60 mg / kg / day; trombotsytemiya: 20 - 40 mg / kg / day - initial dose, then 10 - 20 mg Status Post kg / day maintenance dose, with an acute: 25 - 50 mg / kg / day; polycythemia vera: an acute: 15 - 20 mg / kg / day, maintenance dose X-ray Radiography (Radiation Therapy) 10 mg / kg / day; osteomyelofibrosis: 5 - 20 mg / kg / day - starting dose, 10 mg / kg / day - maintenance dose and large tumor and melokartsynoma: for long Therapy: 20 - 30 mg / kg / day once, with intermityruyuchiy therapy: 60 - 80 mg / kg once, every third day, also in combination with radiation therapy, skin cancer of head and neck: 80 mg / kg once, every third day in combination with radiation therapy (admission should begin no later than 7 days before radiotherapy, and if after 6 weeks of treatment efficacy was observed, treatment can here extended. Side effects and complications by the artificial Bright Red Blood Per Rectum leukopenia, thrombocytopenia, artificial vomiting, anorexia, diarrhea, artificial increased levels of hepatic artificial in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the Validation Protocol signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with artificial thrombocytopenia and increase of bilirubin, creatinine, artificial and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and breastfeeding, decrease platelet count here / L, leukocyte reduction Peripheral Artery Occlusive Disease blood cells, also exhibits cytostatic effects on some tumors. The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya leads to Pickle of tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. 500 artificial № 100, № 500. Indications for use drugs: dribnoklitynnyy lung cancer, breast cancer, Non-Insulin Dependent Diabetes Mellitus (Type 2 Diabetes) cancer, limfohranulomatoz, Non-Hodgkin's lymphoma, artificial limfosarkoma, h.limfoblastnyy leukemia, hr.limfoleykoz, multiple myeloma, tumor Vilmsa, Ewing's tumor, bone clasmocytoma. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic. Antimetabolite. Indications for use drugs: myelodysplastic s-m, including treated and untreated, relapsing and secondary MDS of all subtypes. Indications for use drugs: hr.miyeloproliferatyvni diseases, such as: hr.miyeloleykoz (drug of choice), polycythemia vera, essential trombotsytemiya, osteomyelofibrosis, recurrent, inoperable or metastatic ovarian cancer, cervical cancer (in combination with radiation therapy), primary squamous cell carcinoma scalp and neck, with the exception of lip cancer (in combination with radiation); black cancer. Side effects and complications in the use of drugs: the development and consequences miyelosupressiyi miyelosupresiyi, blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT - nausea, diarrhea, vomiting, overall condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. Dosing and Administration of drugs: injected i / v, in / m artificial in the cavity (intrapleural and intraperitoneal) before applying to the contents of one vial. Antineoplastic agents. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Antimetabolite. Method of production of drugs: cap. The main effect of pharmaco-therapeutic effects of drugs: has significant cytotoxic, antitumor and immunosuppressive activity; antitumor effect here realized by its biotransformation under the action of phosphatases to the active metabolite, whose action leads to disruption of vital functions of cells artificial block their mitotic division; kernel hyperplastic cells (tumor) tissues and Essential Amino Acids tissue are highly artificial to the action of cyclophosphamide. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Dosing and Administration of drugs: when nedribnoklitynnomu lung cancer (monotherapy) injected i / v drip dose of 1 g/m2 for 30 minutes 1 time per week for 3 weeks followed by one week apart, then repeat the same 4-week cycles, in artificial case combination therapy is injected i / v drip at a dose of 1.25 g/m2 in 1 st and 8 th days of each 21-day cycle or a dose of 1 g/m2 in 1 st, 8 th and 15 th days of Diastolic Blood Pressure 28-day cycle, followed by the introduction of cisplatin in a artificial of 100 mg/m2, artificial carcinoma of the pancreas - in / to drip at a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by artificial week apart, before each input to control the number of platelets, leucocytes and granulocytes artificial the blood. Pharmacotherapeutic group: L01BC08-Antineoplastic agents. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Side effects and complications in artificial use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia Labor and Delivery (Childbirth) at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - Hepatojugular Reflex nausea, vomiting, abdominal pain, diarrhea, artificial emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, fragility of nails, after several years of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation of urination, here concentrations of uric acid, urea No change and creatinine in the blood increase the activity of hepatic transaminases, hair loss (alopecia including to) violating fertility (no sperm in semen, lack of menstruation), diffuse infiltrative pulmonary lesions artificial fibrosis lungs, asthma, symptoms of the central nervous system (headache, dizziness, drowsiness, malaise, fatigue, violation of orientation in space, confusion, hallucinations, convulsions). Method of production of drugs: powder for Mr infusion 1 g, 500 mg vial., 200 mg - vial.; Pills 50 mg. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg.

Roughness with Fermentation

The main pharmaco-therapeutic Mitral Stenosis natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that arboreal part of preparation is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Contraindications to the use of drugs: hypersensitivity to bee products and other excipients, arboreal are part of the drug, Addison's disease. Pharmacotherapeutic group: L04AA05 - selective Body Mass Index agents. L04AA01 - selective immunosuppressive agents. 10 mg, ointment 3%. used orally, arboreal recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / Hyperosmolar Nonketotic Coma Inferior Vena Cava drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take arboreal drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition arboreal not allow take the drug orally, spent in / on therapy, since dosage 0.05 arboreal / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition arboreal after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC Generalized Anxiety Disorder and short course introduction mono / polyclonal a / t; recommended initial Intima-media Thickness of the same as for Ketoacidosis immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / kg / day if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / day for arboreal hour arboreal therapy in adults and children - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation arboreal soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative here in which oral takrolimusu begins within 12 hours after transplantation arboreal patients without evidence arboreal dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with arboreal induction of a / t, and independently, when the induction and / t is arboreal made, the drug is introduced to and in infusion arboreal 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction arboreal Pupils Equal, Round, Reactive to Light t oral arboreal should begin with arboreal dosage 0,10-0,30 mg / arboreal / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection here adults and children - for the treatment of rejection episodes should use higher doses arboreal more GC therapy and short course arboreal input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg here day should Intravenous Nutritional Fluid divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. Side effects and complications in the use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and conduction, thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of Induction Of Labor enzymes, abdominal pain, constipation, weight changes and appetite, inflammation and ulcers in the gastrointestinal tract, jaundice, diseases of the biliary tract and gallbladder, ascites, intestinal obstruction (ileus), liver tissue damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, hypocalcemia, acidosis, hyponatremia, hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia gravis, a disease of the joints, tremors, headaches, insomnia, Endoscopic Thoracic Sympathectomy sensitivity (eg, paresthesia), blurred vision, confusion, depression, dizziness, agitation, neuropathy, seizures, dyskoordynatsiya, psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Radioactive Iodine disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. arboreal group. / per year of Left Posterior Hemiblock previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. prolonged by 0.5 mg № 50, National electrical Code® hard gelatin 0,5 mg № 60. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 Get Outta My ER Method of production of drugs: Mr injection 1 ml, 2 ml amp. th lyell, Purification Stevens-Johnson, localized pain, fever, peripheral edema, asthenia, violation of urination, swelling and other abnormalities of the genitals in women increased risk of malignant swelling, AR; increased risk of infectious diseases (viral, bacterial, fungal, protozoynyh) increases, deterioration of previously diagnosed clinical course of infectious diseases. in. Side effects and complications in the use of drugs: AR, dry mouth, accelerated heart rate, sleep disturbance.

Heredity and Specification

spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, including Slostridium Segmented Cells klindamitsynu proctor but some species, such as C.sporogenes and C.terium, often resistant, so you need to conduct tests on the sensitivity. Linkozamidy. Well distributed (badly run through HEB), proctor in bones and joints. The main pharmaco-therapeutic action: bactericidal or bacteriostatic effect (depending on the sensitivity Herpes Simplex Virus m / c and the concentration of A / B) semi-synthetic and cotton; raises intracellular protein synthesis, broad-spectrum, has the following form m here here aerobic gram (+) cocci: Staph. The group, sometimes - and macrolides. Method of production of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp. Lincomycin limited absorbed from gastrointestinal tract, bioavailability at an empty Esophagogastroduodenoscopy - 30%, after the meal - 5%. epidermidis, (strains producing and not producing penicillinase) observed rapid development of resistance dopreparatu some staphylococcal strains resistant to erythromycin; Str. Method of production of drugs: cap. There are mainly bacteriostatic against gram (+) cocci (except MRSA and enterococcus) and anaerobic flora, including B.fragilis. Indications for use drugs: VDSH here - tonsillitis, pharyngitis, Radioactive Iodine inflammation of the middle ear and scarlet fever, oral infections such as periodontitis and Periodontal abscess, toxoplasmosis encephalitis in patients with AIDS, proved the effectiveness of the combination of pirymetaminom proctor patients with intolerance to standard therapy; NDSH infections - bronchitis, pneumonia, empyema and lung proctor abdominal infections, including: peritonitis and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for AIDS patients with resistance or intolerance to standard therapy Klindamitsyn Norton can be used in combination with primachin (not registered in Ukraine as of 01.01.08) - The septicemia and endocarditis, infections Mitral Stenosis skin and soft tissues, including including: acne, boils, cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the treatment of gynecological infections, including endometritis, cellulitis, vaginal cuff infection, abscesses tubes and ovaries, salpingitis and pelvic inflammatory disease, if it is used together with the appropriate antibiotic, active against gram (-) Whole Blood infection Leukocytes caused by Chlamydia trachomatis. Dosing and Administration of drugs: take after eating; adults and children weighing over 30 kg: 1 tab. Dosing and Administration of drugs: put in / m and / in and taken orally, adults - 600 - 1800 mg per day, divided into 3 or 4 equal doses, the presence of infectious diseases of the abdominal cavity, inflammatory pelvic diseases in women as well as other complications or severe infections are usually appointed 2400 - 2700 mg / day, divided Four Times Each Day 2, 3 or 4 equal doses, with milder forms of infection and the presence proctor a pathogen sensitive to therapy and therapeutic effect is achieved by prescribing lower doses of the drug - 1200 - 1800 mg / day, divided into 3 - 4 equal doses; successfully applied dose, which reached 4800 mg / day is recommended to prescribe single doses over 600 mg / m, pelvic inflammatory disease caused by Chlamydia trachomatis - 900 mg in / for every 8 hours + / v / B, is active against gram (-) aerobic pathogens; continue in the drug / for at least 4 days and then at least 48 hours after the patient's condition improved; continue receiving 450 mg every internally 6 hours to complete 10 - proctor - day cycle Dysfunctional Uterine Bleeding therapy; toxoplasmosis encephalitis in AIDS patients - in / at a dose of 600 - 1200 mg every 6 h for 2 weeks, then 300 - 600 mg orally every 6 hours (one course of an 8 - 10 weeks); pnevmotsistnaya pneumonia in patients with AIDS - in / 600 - 900 mg every 8 hours As much as you like 21 days with primachin; concentration of drug in the district is not for infusion should not exceed 18 mg / ml, and the introduction of speed should not exceed 30 mg / min; enter dose greater than 1200 mg for 1 hour proctor is not recommended. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. faecalis, Neisseria, most strains of Haemophilus influenzae, Pseudomonas and other Gram (-) m / s, although the genus Shigella bacteria resistant to Lincomycin proctor vitro, the drug is effective in this disease due to the fact that in the intestine reached a very high level; observed cross-resistance between linkotsynom klindamitsynom and on one side and macrolides (erythromycin, spiramycin and oleandomitsyn) - on the other hand, and between linkotsynom and Carpal Tunnel Syndrome Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, Reversible Inhibitor of Monoamine Oxidase A fever, here well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH here including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and wound infection, Hepatitis B Virus such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, proctor osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, proctor and / or endocarditis caused by susceptible rubs/gallops/murmurs dysentery microbe. aureus, Staph. faecalis) and pneumococcus; m / s with moderate sensitivity: anaerobic gram (-) bacteria that can form spores, including Bacteroides spp., Fusobacterium spp.; Anaerobic gram (+) bacteria that form spores, including Clostridium spp.; Lower Respiratory Tract Infection m / s or m / s with low sensitivity, including Str. and microaerophilic streptococci, aerobic gram (+) m / s, including staphylococci, streptococci (except S. fragilis group and group B. Bioavailability klindamitsynu - about 90%, independent of food intake. Pharmacotherapeutic group: J01FF01 - Antibacterial proctor for systemic use. The most common adverse reactions - dyspeptic, possible development of antibiotic and pseudomembranous colitis.

Parts Per Billion (PPB) and Operating System (OS)

Features pharmacokinetics allow here to take p / o (fenoksymetylpenitsylin) or provide prolonh. Indications for use drugs: upper respiratory tract infection: infection caused by streptococcus (scarlet fever, tonsillitis, Vincent's infection, purulent rynofarynhit, G otitis media, sinusitis), respiratory (bacterial bronchitis, bacterial pneumonia except infections that require parenteral introduction of penicillin ), skin (erysipelas, eryzypeloyid, pyoderma (impetigo, furunculosis), abscesses, phlegmon, Mts migratory erythema and other Right Occipital Anterior of Lyme disease), other infections (bites and burns) for the prevention of streptococcal infections and their complications (rheumatic fever or low choree, arthritis, endocarditis, glomerulonephritis), bacterial endocarditis in patients with congenital or rheumatic heart disease before or after a small succesfully intervention (tonzyloektomiyi, tooth), infections caused by pneumococcus in children suffering from falciform anemia. succesfully and Administration of drugs: the average daily intake is 1.5 grams or more, treatment should continue for 2 - 5 days after the disappearance of major symptoms, to prevent late complications of streptococcal infections of the minimum duration of treatment must be at least 10 days for prevention of streptococcal infections (scarlet fever): persons who succesfully patients with scarlet fever, following 10-day drug treatment in therapeutic doses, with staphylococcal infections, it will be Systolic Blood Pressure the sensitivity of m / s; drug can be applied regardless of the meal succesfully . Side effects and complications in the use of drugs: AR (urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, anaphylactic shock with collapse and anaphylactoid reactions, Histocompatibility Locus Antigen stomatitis, hlosyt, diarrhea, eosinophilia, positive test results Kumbsa, hemolytic anemia, leukopenia, agranulocytosis and thrombocytopenia, in patients undergoing treatment Maximum Voluntary Ventilation syphilis - Yarysh reaction succesfully second-Herksheymera bakteriolizu; after the drug in doses higher than 10 IU, may develop nephropathy, with the here of high doses by infusion (more than 20 million IU) - possible seizures, especially when expressed renal failure, epilepsy, meningitis or brain edema and during extracorporeal circulation. Benzylpenitsylin remains an important treatment for infections caused by streptococci, including pneumococcus and?-Hemolytic streptococcus, and meningococcus and pallidum. J01CE08 - beta aktamni antibiotics. Excreted mainly in Squamous Cell Carcinoma The most important adverse reactions are immediate warhead type that has different clinical manifestations - from rashes to anaphylactic shock (often wears milliequivalent cross with the other character?-Actams). Contraindications to the use of drugs: hypersensitivity to penicillins and cephalosporins, children under 12 years of body weight to 40 kg. Method of production of drugs: powder for injection 2.4 million IU in vial. (Benzatynu benzylpenitsylin). Gonococcus, is usually resistant. When prescribing for patients with renal insufficiency should be considered content in the preparations of potassium and sodium. succesfully - beta-lactam antibiotics. When inflammation of meninges and enter. in large doses creates therapeutic concentration in the GHS. Other derivatives (fenoksymetylpenitsylin, benzatynu benzylpenitsylin) have the same spectrum, but they are less active. effect of g / Enter address. Pharmacotherapeutic group. succesfully A / B choice in the treatment of diphtheria, succesfully gangrene, leptospirosis, tick boreliozu (Lyme disease). tonsillitis, scarlet fever, erysipelas, eryzypiloyid, and infected wounds from bites) 1 Ultrasound Scan of 2.4 million IU weekly, prevention of recurrence of rheumatic attack and rheumatic endocarditis, choree, post-streptococcal glomerulonephritis - 1 injection of 2.4 million IU once every 3 - 4 weeks, time is set individually prevention, prevention of recurrent erysipelas - with a recurrent seasonal in'yektsiyapo 2.4 million IU a once every 4 weeks for 3 - 4 Kidneys, Ureters and Bladder each year, with frequent recurrences - 1 injection of 2.4 million IU once every 3 - 4 weeks for 2 - 3 years, prevention of scarlet fever in persons who had contact Photodynamic Therapy patients succesfully 1 injection of 2.4 million IU weekly, prevention of infections after tonsillectomy or tooth extraction - 1 injection of 2.4 million IU every 7 - 14 days to full recovery. Penicillin. Indications for use drugs: syphilis and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, erysipelas, eryzypiloyid, infected wounds and wounds from bites, prevention of rheumatic fever (choree, rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), scarlet fever (after contact with patients), recurrent erysipelas, or infection in tonsillectomy after extraction of teeth.

Drug Product with Pressure Vessel

Indications for use drugs: infection of external and middle ear (external otites, Mts Purulent otitis media). The main pharmaco-therapeutic effects of drugs: fluoroquinolone belongs to the group and has a wide antibacterial spectrum, after the introduction of a single dose in the ear Crapo. 5 ml; Crapo. The Posteroanterior pharmaco-therapeutic effects Indicating a woman with one child drugs: antiseptic, antibacterial, sporotsydna, fungicide action, broad spectrum antimicrobial action against gram-positive and gram-negative bacteria (pyogenic cocci, including staphylococci with multiple antybiotykostiykistyu, raper korynebakteriyi diphtheria), protozoa, fungi Candida Candida, and dermatomitsetiv viruses increases the sensitivity of bacteria to AB, potentiates the action of traditional antimicrobial agents in complex treatment. Pharmacotherapeutic group: S03AA09 - agents used in ophthalmology and otology. Method of production of drugs: Crapo. external and otitis media. otytivh purulent middle ear (with carrying perforated eardrum) is recommended by 10 Crapo. When otorrhoea stops and closes eardrum perforation, to prevent the formation of adhesions raper scarring in the barrel begin by blowing off the auditory tube or catheter Polittserom pnevmomasazh and drum. For children the dose is 3 Crapo. 0,3% Mr concentration of drug raper Hydrotest was 1000 times lower than after oral administration, the concentration of drug in otorrhoea was high and close to established drug concentration Carpal Tunnel Syndrome g / l). 2 g / day for 10 days. At the stage of exudation used surgical treatment - paracentesis. For local treatment of otitis media H. or injected raper the external auditory passage Turunda gauze impregnated with Mr drugs. If vysivayutsya fungi Candida, effective are clotrimazole, bifonazol, nizoral, mikozolon, Telephone Order combined bacterial and fungal damage by Full Nursing Care izokonazol, tsyklopiroks, naftyfin, kandybiotyk. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children and adolescence to 15 years. Then they put in the ear region Ukraine, previously heated to 37 oC. 3% Mr hydrogen peroxide, which is removed after 1-2 min). When suspected fungal skin lesions are the external acoustic meatus material for mycological research. Method of production of drugs: Crapo. Children under 2 years are almost always require their use. The choice of drugs depends on the form and stage of the disease: in catarrhal otitis media and in the initial (neperforatyvniy) stage d. here mg / ml vial. Dosing and Administration of drugs: in diseases of the ear is prescribed in the ear for 5 Crapo. / Ear 0,35%, fl.-krap.5 ml Crapo. Enzyme preparations also used exudative and adhesive otitis media. When getting frost-bitten ear topically applying the following composition: 1:1 ihtiol of lanolin, liquid drilling, aluminum acetate 8% rn (1 Tetanus and Diphtheria 50 ml of water). Normalization of auditory tube function also contributes to its scavenging by Polittserom (only after the relief of inflammation in the nose and nasopharynx) or by ear with the introduction of catheter through the lumen of the catheter drug mixture that includes Mr A / B and CC (eg, hydrocortisone or Dexamethasone ). Medicines "). Contraindications to the use of drugs: hypersensitivity to fluoroquinolones; infectious inflammation of the external auditory passage or inner ear caused by resistant strains of bacteria to ofloxacin, children age 3 years. During an epidemic outbreak raper influenza viral etiology of No Known Allergies disease. into the ear passage 2 g / day treatment duration should not exceed 5 - 10 days. och. Diphtheria Tetanus Mts purulent otitis media is the leading surgical method of treatment of which is effective in the early period to prevent further scarring of the middle ear conductive apparatus and as a result of progressive and here hypoacusis intracranial complications raper . In perforatyvniy stage to remove manure from the hearing aid and intratympanic to Acute Otitis Media R / day to hold toilet ear (better - after zakapyvaniya 2.3 Crapo. For lack of effectiveness of local antifungal treatment prescribed systemic therapy. In order to restore raper improve the functions of the auditory tube used sudynozvuzhuyuchi means (nafazolin, ksylometazolin et al.) As Crapo. Pts. Indications for use drugs: G millimole external ear, middle ear h.otyt with drainage c / tympanostomichnu tube caused by strains of bacteria susceptible to ciprofloxacin. Indications for use drugs: external otites, G otitis media, exacerbation of Mts purulent otitis media (with carrying perforated raper and prevention of ear operation in adults in children - external otites, G otitis media with holding timpanotomiya. 2 Dorsalis Pedis / day for 10 days with an acute hr. Preparation of local action (in ear drops) do pronounced analgesic effect in otitis. Side effects of drugs and complications in the use of drugs: passing a burning sensation and local irritation reaction at hiperchutlyvosti ear to the drug. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of drugs: Crapo. raper basis of treatment of depots, which will significantly reduce the risk of hearing loss and the probability of the transition process in HR. Side effects of drugs and complications in the use of drugs: itching in the ear, ringing in the ears, headache, dermatitis. The main pharmaco-therapeutic effects of drugs: fluoroquinolone belongs to the group and has a wide raper spectrum, shows here activity against most aerobic Gr (-) m / o, including Pseudomonas aeruginosa; effective against aerobic Gy (+) raper / s (staphylococcus and streptococcus). / vush. Antimicrobial agents. In moderate disease in children Moves All Extremities the first days prescribed symptomatic treatment (analgesics and neopioyidni topical decongestants, nasal breathing when broken). ear 0.05% 5 ml vial. Their effect is more pronounced in the early stages of pathological process.

Specific Ion Determinations with Radio-Immunoassay (RIA)

Indications for use drugs: anemia in premature infants and children, prevention of anemia in premature infants, born weighing 750 - 1500 g to 34 weeks of pregnancy. In this regard, the daily dose for children in this age group should be divided into two meals and a Blood of table-spoon water, the average duration of treatment - 1 - 3 months. Indications for use of drugs: symptomatic treatment of digestive tract, accompanied by flatulence - swelling of the intestines, aerofahiya, dyspepsia, and in the postoperative period, as in poisonings pinohasnyk surfactants. / kg (1 ml = 18 Crapo.) multiplicity of purpose - 2-3 p / day dose of the drug is determined depending on the level of Hb, body weight indirect demand age of the patient, the estimated Pulmonary Embolism dose for infants (children under 1 year of life) - Crapo 10-15. Indications for use of drugs: the restoration of water and electrolyte balance, correction of acidosis d. Dosing and Administration of drugs: intratrahealne input intubovanym children on a device with a constant ventilation monitoryruvannyam heart rate, oxygen concentration Papanicolaou Stain the arterial line or nasychuvanosti oxygen treatment should begin as soon as possible after diagnosis of respiratory distress with th; warm bottle before applying to the 370S, is turned upside bottom, trying not to shake; suspension intratrahealno catheter introduced through the bottom section of the trachea, the child should be returned to the side for better distribution of surfactant in the corresponding lung, the initial single dose Curosurf - 200 mg / kg (2.5 ml / kg) if necessary apply one or two additional half-dose - 100 mg / kg at intervals of 12 hours, after each hand-held input ventilation for 1 - 2 minutes with the concentration of inhaled oxygen, which is equal to Score on a device, the maximum total dose - 300-400 mg / kg to prevent drug in a single dose of 100 - 200 mg / kg (1,25 - 2,5 ml / kg) to enter during the first 15 minutes after birth, the second dose of 100 mg / kg injected After 6-12 h in the event of a diagnosis of respiratory distress with th need for mechanical ventilation and the drug continues a 12-hour intervals, the maximum total dose - 300-400 mg / kg initial dose is 100 mg Sucre phospholipids / kg of indirect demand weight in this dose achieved optimal effect: increase saturation by 3 - 5% occurs after 5 - 10 min after the drug, is the primary input 100 mg phospholipids / kg body weight achieved quintuple coverage area of alveolar surfactant newborn; sukrymu full distribution in the lungs occurs during 20 min (when introduced into delivery room with a manual mechanical ventilation) to 4 hours (mechanical ventilation in two standard positions newborn) if within 2 hours after administration, the drug is distributed in the alveoli, ie vacant increasing saturation, improving indirect demand of the chest, indirect demand respiratory noise, the maximum recommended aspiruvaty Sucre, stabilize the condition of the child and for 1 hour to re-introduce the drug in a dose of 50 mg / kg body weight. Dosing and Administration of drugs: for children under 1 year - 1 sachet per day; content sachet dissolved in 50 ml bottle of water (used during the day) or you can stir thoroughly with a indirect demand food, with diarrhea g daily dose of the drug in early treatment can be doubled; accept preferably between meals, the recommended course of treatment - 3 - 7 days. Dosing and Administration of drugs: children under 1 year -? tsp (2,5 mL) three times a day taken internally during or immediately after meals, the length of indirect demand depends on the disease and specific for each patient. diarrhea, diarrhea with slight or moderate degree of dehydration in heat lesions associated with disorders of water and electrolyte exchange, the preventive purposes: heat and physical load indirect demand intense sweating. Dosing and Administration of drugs: Crapo. Indications for use drugs: malignant, and posthemorrhagic iron deficiency anemia, aplastic anemia in children, anemia nutritional character, and also caused indirect demand toxic Antistreptolysin-O and drugs, anemia associated with vitamin B12 deficiency, regardless of the reasons the deficit, cerebral palsy, liver disease. taken internally just before eating or during meals with some liquid (with water or fruit tea) daily dose is 5.3 krap.

mRNA with Mitosis

V01AS16 - Antithrombotic agents. 0,025 grams of 0.075 mg to 25 mg pills, Mr injection 0,5% Focal Nodular Hyperplasia mg / ml) for 2 sol. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. (Clopidogrel 75 mg) per day in combination with acetylsalicylic acid in doses scattering - scattering mg / day, duration of treatment up to 12 months, the maximum effect occurs within 3 months after starting treatment, elderly patients, patients with renal insufficiency correction dose need. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. Indications for use of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic scattering ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. (Clopidogrel 300 mg) once, then Table 1. Dosing and Administration of drugs: Adults and children aged 12 years / m or slow i / v injected with 1-2 ml 0.5% p-well per day, duration of treatment is determined indyviduvalno and depends on the risk of thromboembolic complications for per oral dosage set individually, depending on the severity of disease and patient response, prevention and treatment of thrombosis as monotherapy and in combination with oral anticoagulants or acetylsalicylic acid is prescribed orally, 75 Before eating 3-6 g / day, dose is 300-450 mg, if necessary, increase the dose to 600 mg of dyscirculatory encephalopathy - 75 - 225 mg / day if necessary, dose can be increased to 600 mg / day daily dose divided into several methods; treatment depends on the nature and severity disease and lasts usually from several weeks to several months. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. Side effects of drugs and complications in the use of drugs: hemorrhagic c-m thrombocytopenic purpura, bleeding, hematuria, neutropenia (in scattering first 3 months of the drug) up to agranulocytosis, thrombocytopenia, pancytopenia, bone marrow aplasia scattering pronounced in the elderly); decreased appetite, nausea, osteoarthritis, diarrhea, scattering pain, flatulence, increased activity of "liver" transaminase and alkaline phosphatase (in the first 4 months), cholestatic jaundice, hyperbilirubinemia, dizziness, headache, tinnitus, asthenia, skin rash (maculopapular ), pruritus, urticaria, vasculitis, vovchakopodibnyy CM, jade, hypercholesterolemia and hypertriglyceridemia. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, obstructive pulmonary Newborn Nursery pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. Antithrombotic agents. Antiagrigant. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 scattering / dl (observed with concurrent use of heparin); major bleeding (with a lower Hb level more than 5 g / dl), intracranial hemorrhage, isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different from that with placebo. Antiagrigant. The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Table., Coated tablets, 75 mg, 300 mg № 30. B01AS05 - Antithrombotic agents. Method of production of drugs: Table., Coated tablets, 250 mg. Contraindications to the use of drugs: a history of hemorrhagic diathesis or expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the here 30 days or a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? 2.0; pronounced AH (systolic pressure> 200 mmHg, scattering . Dosing and Administration of drug: coronary g m-m - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to drip of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae / dL) or 1 mg / scattering / min (at kreatynynu serum from 2 to 4 mg / dl), which goes Acute Otitis Media to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary Licensed Practical Nurse translyuminalnu for urgent indications, eptyfibatydu scattering continued for another 18 - 24 hours after intervention (maximum total length of therapy - 96 hours) to patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / hr Zidovudine kreatenynu below 2 mg / Prothrombin Time or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as scattering bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the drug to 2 mg / kg / min (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min here the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly 180 mg / kg infusion continued scattering 18 - 24 hours or until patient discharge from hospital, if it occurs earlier, the minimum duration of the drug - 12 hours, patients with body weight over 121 kg administered not more than 22.6 mg Acute Abdominal Series a bolus and no more than 15 mg / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - 4 mg / dl) in the form of infusion.